We studied the expression of MMP-2, MMP-9, and inhibitor TIMP-1 in myocardial autopsy samples from subjects of different age and in cardiomyocyte cultures in the norm and in dilated cardiomyopathy. In autopsy samples of normal myocardium and in cardiomyocyte cultures, expression of molecules involved in extracellular matrix remodeling did not change during aging. In dilation cardiomyopathy, expression of MMP-2, MMP-9, and TIMP-1 and their ratios in autopsy material and in cultures was elevated by 1.5-9 times. Remodeling of extracellular matrix plays an important role in the pathogenesis of dilated cardiomyopathy. MMP-2, MMP-9, and their inhibitor TIMP-1 and the MMP/TIMP ratios can be regarded as promising predictors of dilated cardiomyopathy and used for evaluation of the effectiveness of treatment of this conditions in patients of different ages.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gurevich MA, Arkhipova LV. Principles of therapy of chronic heart failure in patients with dilated cardiomyopathy. Bol. Serdtsa Sosudov. 2011;6(1):37-40. Russian.
Tereshchenko SN, Alaeva EN, Narusov OYu, Kochetov AG, Skvortsov AA. Diagnosis and treatment of dilated cardiomyopathy in common clinical practice (Primary data of the Russian register of dilated cardiomyopathy). Kardiol. Vestn. 2014;9(2):54-61. Russian.
Bornstein P, Sage EN. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell. Biol. 2002;14(5):608-616.
Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix Metalloproteinase Inhibition after Myocardial Infarction: a new approach to prevent heart failure? Circ. Res. 2001;89(3):201-210.
Ju C, Ye M, Li F. Plasma brain natriuretic peptide, endothelin-1, and matrix metalloproteinase 9 expression and significance in Type 2 diabetes mellitus patients with ischemic heart disease. Med. Sci. Monit. 2015;21:2094-2099.
Jungbauer CG, Riedlinger J, Block D, Stadler S, Birner C, Buesing M, König W, Riegger G, Maier L, Luchner A. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomark. Med. 2014;8(6):777-789.
Li X, Lu Y, Sun Y, Zhang Q. Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model. Int. J. Clin. Exp. Pathol. 2015;8(6):7247-7253.
Lubos E, Schnabel R, Rupprecht HJ, Bickel C, Messow CM, Prigge S, Cambien F, Tiret L, Münzel T, Blankenberg S. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the atherogene study. Eur. Heart J. 2006;27(2):150-156.
Morine KJ, Paruchuri V, Qiao X, Mohammad N, Mcgraw A, Yunis A, Jaffe I, Kapur NK. Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis. Biomarkers. 2016;21(1):91-97.
Nepomnyashchikh LM, Lushnikova EL, Bakarev MA, Nikityuk DB, Yuzhik EI, Mzhelskaya MM, Nepomnyashchikh RD, Klinnikova MG, Karpova AA. Immunohistochemical analysis of MMP-2 expression in the myocardium during the postinfarction period. Bull. Exp. Biol. Med. 2015;159(4):505-510.
Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Küry P, Strauer BE, Schwartzkopff B. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin. Res. Cardiol. 2006;95(5):261-269.
Rita Balistreri C, Allegra A, Crapanzano F, Pisano C, Ruvolo G. Matrix Metalloproteinases (MMPs), their genetic variants and miRNA in mitral valve diseases: potential biomarker tools and targets for personalized treatments. J. Heart Valve Dis. 2016;25(4):463-474.
Rutschow S, Leschka S, Westermann D, Puhl K, Weitz A, Ladyszenskij L, Jaeger S, Zeichhardt H, Noutsias M, Schultheiss HP, Tschope C, Pauschinger M. Left ventricular enlargement in coxsackievirus-B3 induced chronic myocarditis-ongoing inflammation and an imbalance of the matrix degrading system. Eur. J. Pharmacol. 2010;630(1-3):145-151.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 4, pp. 236-240, October, 2017
Rights and permissions
About this article
Cite this article
Antonov, I.B., Kozlov, K.L., Pal’tseva, E.M. et al. Matrix Metalloproteinases MMP-1 and MMP-9 and Their Inhibitor TIMP-1 as Markers of Dilated Cardiomyopathy in Patients of Different Age. Bull Exp Biol Med 164, 550–553 (2018). https://doi.org/10.1007/s10517-018-4030-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-018-4030-0